OREX Financial Facts

Net loss per share: 0.09
Research and development: 10.72M
See Full Income Statement

Additional paid-in capital: 569.36M
Other assets: 426K
See Full Balance Sheet

Orexigen Therapeutics (OREX) Earnings

  |   Expand Research on OREX
Next EPS Date 5/22/15 *Est. EPS Growth Rate +100.0% *Last Qtr.
Average EPS % Beat Rate +14.7% Revenue Growth Rate -97.3% *Last Qtr.
Average % Move 1-Wk after EPS +15.6% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/25/15 Q414 $0.00$0.21 -$0.21$22.95M$49.65M N/A Details
11/10/14 Q314 $0.09-$0.13 +$0.22$30.9M$8.93M N/A Details
8/7/14 Q214 -$0.21-$0.21 $0.00$857K$1M N/A Details
3/12/14 Q413 -$0.21-$0.19 -$0.02$857M$900M N/A Details
11/12/13 Q313 -$0.19-$0.18 -$0.01$857K$800K N/A Details
8/6/13 Q213 -$0.19-$0.19 $0.00N/A$900K N/A Details
3/13/13 Q412 -$0.41-$0.44 +$0.03$857K$910K N/A Details
11/7/12 Q312 -$0.44-$0.30 -$0.14$857K$890K N/A Details